These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 33151853)

  • 1. [Melanoma therapeutic escape: the biomechanical track].
    Lecacheur M; Girard CA; Deckert M; Tartare-Deckert S
    Med Sci (Paris); 2020 Nov; 36(11):961-965. PubMed ID: 33151853
    [No Abstract]   [Full Text] [Related]  

  • 2. Phenotypic tumour cell plasticity as a resistance mechanism and therapeutic target in melanoma.
    Roesch A; Paschen A; Landsberg J; Helfrich I; Becker JC; Schadendorf D
    Eur J Cancer; 2016 May; 59():109-112. PubMed ID: 27023049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macrophages: Key orchestrators of a tumor microenvironment defined by therapeutic resistance.
    Long KB; Collier AI; Beatty GL
    Mol Immunol; 2019 Jun; 110():3-12. PubMed ID: 29273393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First person: Antoni Ribas, MD, PhD: The physician-scientist from the University of California at Los Angeles researches how new therapies for patients with advanced malignant melanoma can help to overcome resistance to treatment.
    Printz C
    Cancer; 2018 Mar; 124(6):1097-1098. PubMed ID: 29509327
    [No Abstract]   [Full Text] [Related]  

  • 5. The great escape: tumour cell plasticity in resistance to targeted therapy.
    Boumahdi S; de Sauvage FJ
    Nat Rev Drug Discov; 2020 Jan; 19(1):39-56. PubMed ID: 31601994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions.
    Sucker A; Zhao F; Pieper N; Heeke C; Maltaner R; Stadtler N; Real B; Bielefeld N; Howe S; Weide B; Gutzmer R; Utikal J; Loquai C; Gogas H; Klein-Hitpass L; Zeschnigk M; Westendorf AM; Trilling M; Horn S; Schilling B; Schadendorf D; Griewank KG; Paschen A
    Nat Commun; 2017 May; 8():15440. PubMed ID: 28561041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Normalization Cancer Immunotherapy for Melanoma.
    Vesely MD; Chen L
    J Invest Dermatol; 2020 Jun; 140(6):1134-1142. PubMed ID: 32092349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer Stem Cells and Immunosuppressive Microenvironment in Glioma.
    Ma Q; Long W; Xing C; Chu J; Luo M; Wang HY; Liu Q; Wang RF
    Front Immunol; 2018; 9():2924. PubMed ID: 30619286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Contribution of B lymphocytes in acquired resistance to targeted therapies in metastatic melanoma].
    Fourneaux C; Dubois B
    Med Sci (Paris); 2018 Oct; 34(10):875-878. PubMed ID: 30451659
    [No Abstract]   [Full Text] [Related]  

  • 10. How Tumor Cell Dedifferentiation Drives Immune Evasion and Resistance to Immunotherapy.
    Li J; Stanger BZ
    Cancer Res; 2020 Oct; 80(19):4037-4041. PubMed ID: 32554552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melanoma-induced immunosuppression and its neutralization.
    Umansky V; Sevko A
    Semin Cancer Biol; 2012 Aug; 22(4):319-26. PubMed ID: 22349515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hair Depigmentation and Hair Loss in Advanced Melanoma Treated with Combined Immunotherapy and Targeted Therapy.
    Dimitriou F; Mangana J; Dummer R
    Acta Derm Venereol; 2020 Jan; 100(1):adv00007. PubMed ID: 31626322
    [No Abstract]   [Full Text] [Related]  

  • 13. Rationale for New Checkpoint Inhibitor Combinations in Melanoma Therapy.
    Mandalà M; Tondini C; Merelli B; Massi D
    Am J Clin Dermatol; 2017 Oct; 18(5):597-611. PubMed ID: 28432648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COX-2 as a potential biomarker and therapeutic target in melanoma.
    Tudor DV; Bâldea I; Lupu M; Kacso T; Kutasi E; Hopârtean A; Stretea R; Gabriela Filip A
    Cancer Biol Med; 2020 Feb; 17(1):20-31. PubMed ID: 32296574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges and Opportunities of Neoadjuvant Treatment in Locally Advanced Melanoma.
    McKean MA; Amaria RN
    Am J Clin Dermatol; 2018 Oct; 19(5):639-646. PubMed ID: 30039289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The tumour microenvironment shapes dendritic cell plasticity in a human organotypic melanoma culture.
    Di Blasio S; van Wigcheren GF; Becker A; van Duffelen A; Gorris M; Verrijp K; Stefanini I; Bakker GJ; Bloemendal M; Halilovic A; Vasaturo A; Bakdash G; Hato SV; de Wilt JHW; Schalkwijk J; de Vries IJM; Textor JC; van den Bogaard EH; Tazzari M; Figdor CG
    Nat Commun; 2020 Jun; 11(1):2749. PubMed ID: 32488012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor Plasticity and Resistance to Immunotherapy.
    Horn LA; Fousek K; Palena C
    Trends Cancer; 2020 May; 6(5):432-441. PubMed ID: 32348738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Influence of Tumor Microenvironment on Immune Escape of Melanoma.
    Simiczyjew A; Dratkiewicz E; Mazurkiewicz J; Ziętek M; Matkowski R; Nowak D
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33171792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OMIC signatures to understand cancer immunosurveillance and immunoediting: Melanoma and immune cells interplay in immunotherapy.
    León-Letelier RA; Bonifaz LC; Fuentes-Pananá EM
    J Leukoc Biol; 2019 May; 105(5):915-933. PubMed ID: 30698862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel therapies for unresectable and metastatic melanoma.
    Karimkhani C; Reddy BY; Dellavalle RP; Sundararajan S
    BMJ; 2017 Nov; 359():j5174. PubMed ID: 29191943
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.